Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.43 |
| ▸ | GABRE | P78334 | 1/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23047021 | 0.84 | TSHR (0.44) | TSHRL3MBTL1TDP1MAOAMAOB | |
| SCHEMBL27257191 | 0.81 | IDO1 (0.48) | GABRG2GABRB3GABRA3GABRA1LMNA | |
| SCHEMBL27988771 | 0.80 | IDO1 (0.47) | GABRG2GABRB3GABRA3GABRA1LMNA | |
| SCHEMBL4274920 | 0.77 | LMNA (0.55) | GABRG2GABRB3GABRA5GABRA3GABRP | |
| SCHEMBL29699550 | 0.74 | NPC1 (0.56) | CYP2C19MAPTMAOAMAOBRAB9A | |
| SCHEMBL28627959 | 0.73 | PKM (0.46) | GABRG2GABRB3GABRA5GABRA3GABRP | |
| SCHEMBL27514407 | 0.73 | IDO1 (0.35) | MAPTTDP1MAOAHTTIDO1 | |
| SCHEMBL1186713 | 0.73 | RAB9A (0.58) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL5612692 | 0.73 | BRD4 (0.56) | L3MBTL1MAPTMAPK1TDP1LTA4H | |
| SCHEMBL2524154 | 0.73 | L3MBTL1 (0.52) | PKMTSHRLMNACYP1A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084077-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-13 | — | — | US | disclosed |
| US-12091409-B2 | Ether linked triazoles as NRF2 activators | ASTEX THERAPEUTICS LIMITED (GB) | 2024-09-17 | — | — | US | disclosed |
| US-20220089590-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2022-03-24 | — | — | US | disclosed |
| EP-3555082-B1 | ETHER LINKED TRIAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-20220002272-A1 | BISARYL LACTAMS AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| US-11059816-B2 | Ether linked triazoles as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-13 | — | — | US | disclosed |
| EP-3796906-A1 | INDANES AS NRF2 ACTIVATORS | GlaxoSmithKline Intellectual Property Management Limited (GB) | 2021-03-31 | — | — | EP | disclosed |
| EP-3555068-B1 | 3-OXO-1,4-DIAZEPINYLE COMPOUNDS AS NRF2 ACTIVATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| US-20200071317-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
| EP-3555082-A1 | ETHER LINKED TRIAZOLES AS NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-23 | — | — | EP | disclosed |
| EP-0181212-B1 | LIQUID DETERGENT COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1988-11-09 | — | — | EP | disclosed |
| US-4671894-A | MIXTURE OF ANIONIC, NONIONIC, AND ZWITTERIONIC SURFACTANTS | THE PROCTER & GAMBLE COMPANY (US) | 1987-06-09 | — | — | US | disclosed |
| EP-0107946-B1 | LIQUID DETERGENT COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1987-03-11 | — | — | EP | disclosed |
| EP-0181212-A1 | Liquid detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1986-05-14 | — | — | EP | disclosed |
| EP-0062371-B1 | LIQUID DETERGENT COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1985-07-03 | — | — | EP | disclosed |
| EP-0039110-B1 | LIQUID DETERGENT COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1985-01-02 | — | — | EP | disclosed |
| EP-0125854-A2 | Liquid detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1984-11-21 | — | — | EP | disclosed |
| EP-0107946-A1 | Liquid detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1984-05-09 | — | — | EP | disclosed |
| EP-0062371-A1 | Liquid detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1982-10-13 | — | — | EP | disclosed |
| EP-0039110-A1 | Liquid detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1981-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059816-B2 | Ether linked triazoles as NRF2 activators | NFE2L2, KEAP1, NQO1 | GABRG2 2580/4885GABRB3 1257/4885GABRA5 1778/4885 |
| US-20220089590-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | GABRG2 2580/4885GABRB3 1257/4885GABRA5 1778/4885 |
| US-20250084077-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | GABRG2 2580/4885GABRB3 1257/4885GABRA5 1778/4885 |
| US-12091409-B2 | Ether linked triazoles as NRF2 activators | NFE2L2, KEAP1, NQO1 | GABRG2 2580/4885GABRB3 1257/4885GABRA5 1778/4885 |
| US-20200071317-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | GABRG2 2580/4885GABRB3 1257/4885GABRA5 1778/4885 |
| US-20220002272-A1 | BISARYL LACTAMS AS NRF2 ACTIVATORS | KEAP1, NFE2L2, NQO1 | GABRG2 2021/4885GABRB3 1109/4885GABRA5 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.